AVROBIO, INC.

AVRO NASDAQ
19.16
+2.74
+16.69%
After Hours: 19.10 -0.06 -0.31% 19:11 07/16 EDT
Open
17.25
Prev Close
16.42
High
20.25
Low
16.84
Volume
653.53K
Avg Vol (3M)
147.01K
52 Week High
53.70
52 Week Low
11.85
% Turnover
2.93%
Market Cap
427.53M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers AVROBIO, INC. AVRO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

AVROBIO, Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
MORE >

Recently

Name
Price
%Change